arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

BIOCRYST PHARMACEUTICALS INC

BCRX
$9.37 ▲ +0.07 (+0.75%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
18 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
62
Health
Fair
Moderately Bullish
auto_awesome

Analytical Summary

BIOCRYST PHARMACEUTICALS INC demonstrates solid fundamentals with strength in Profit Margin (%). However, watch Return on Common Equity (%) which shows concerning trends. Overall, the data suggests a moderately positive outlook with manageable risks.

Market Cap $2.0B
Dividend Yield
Revenue Growth 94.1%
Op. Margin 39.0%
ROIC -282.4%
FCF / Share $1.65
Trailing P/E 7.4x
Price / Book
FCF Yield 17.7%
Debt / Equity 0.00
info Valuation on last close. End-of-day price, Aug 7, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$874.84M
↑ +94.1%
Net Income Profit after all expenses
$263.86M
↑ +396.9%
Operating Margin Operating profit as % of sales
39.0%
↑ +7008.2% 93th
FCF / Share Free cash flow per share
$1.65
↑ +757.6%
Long-Term Debt Long-term obligations
$0.00
↓ -100.0%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
93
Returns
1
Financial Health
91
Cash Quality
76

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters